A new clinical trial from drugmaker Eli Lilly shows that Zepbound and Mounjaro reduced obstructive sleep apnea symptoms. Tirzepatide, the main ingredient in these medications, reduced symptom severity by nearly two-thirds. Around 20% of participants taking tirzepatide experienced weight loss.